FDA Drug Approval Summary: Pegaspargase (Oncaspar®) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL)
2007; AlphaMed Press; Volume: 12; Issue: 8 Linguagem: Inglês
10.1634/theoncologist.12-8-991
ISSN1549-490X
AutoresPatricia A. Dinndorf, Joseph E. Gootenberg, Martin H. Cohen, Patricia Keegan, Richard Pazdur,
Tópico(s)Pharmaceutical studies and practices
ResumoLearning Objectives After completing this course, the reader will be able to: Describe the effect of pegylation on asparaginase pharmacokinetics and immunogenicity.Identify the current pegaspargase indications.Discuss the advantages of pegaspargase treatment.Outline the clinical trial design leading to pegaspargase approval by the FDA.List the major adverse events associated with pegaspargase treatment. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
Referência(s)